Global Raynauds Disease Treatment Market Projected to Strengthen in Value and Scale by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 What Is the Predicted Market Size and CAGR of the Raynauds Disease Treatment Market by the End of the 2029?
 The raynauds disease treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing awareness of autoimmune disorders, improved diagnostic capabilities, expanded use of calcium channel blockers, an increase in connective tissue disorders, and a surge in the geriatric population.
 
 The raynauds disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing use of telehealth for vascular consultations, expansion of personalized medicine, increased research on endothelial dysfunction, rising prevalence due to climate extremes, and growth in healthcare infrastructure. Major trends in the forecast period include the integration of AI in early diagnosis and disease monitoring, advancements in digital thermal monitoring devices, the development of targeted biologics, advancements in cell therapy and gene editing, and telemedicine and digital health technologies.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24680&type=smp
 
 What Are the Significant Market Forces Driving the Raynauds Disease Treatment Market Performance?
 The increasing prevalence of autoimmune diseases is expected to propel the growth of the raynauds disease treatment market going forward. Autoimmune diseases refer to conditions in which the immune system mistakenly attacks the body’s own healthy tissues, causing inflammation and damage. The rise in prevalence of autoimmune diseases is due to people living in more urbanized and sanitized environments, leading to less immune system training, and modern lifestyle factors such as poor diet, stress, and environmental pollutants. Raynaud’s disease treatment helps the autoimmune disease by allowing better management of symptoms, reducing tissue damage, and preventing complications that arise from impaired blood flow. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based governmental organization, in 2021–22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year’s 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the raynauds disease treatment market.
 
 Rising Healthcare Expenditure Driving Growth Of The Market Due To Enhanced Access And Advanced Care
 
 The rising healthcare expenditure is expected to propel the growth of the raynauds disease treatment market going forward. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, and health-related resources within a given period. Healthcare expenditure is rising significantly as the aging population grows, leading to a higher demand for medical services, long-term care, and age-related treatments, which collectively place a greater financial burden on healthcare systems. Healthcare expenditure improves Raynaud’s disease treatment by enabling better access to medications, advanced diagnostics, specialized care, research for new therapies, and public awareness programs that help manage symptoms effectively. For instance, in April 2025, according to the American Medical Association, a US-based professional association, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the raynauds disease treatment market.
 
 Which Segments Are Likely to Shape the Future Outlook of the Raynauds Disease Treatment Market?
 The raynauds disease treatment market covered in this report is segmented — 
 
 1) By Treatment Type: Medication, Thermal Therapies, Surgical Procedures, Alteative Therapies
 2) By Drug Class: Calcium Channel Blockers, Vasodilators, Antiplatelet Agents
 3) By Route of Administration: Oral, Topical, Injectable, Intravenous
 4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmacies
 
 Subsegments:
 1) By Medication: Calcium Channel Blockers, Alpha Blockers, Vasodilators, Topical Nitrates, Selective Serotonin Reuptake Inhibitors (SSRIs), Phosphodiesterase Inhibitors, Angiotensin Receptor Blockers (ARBs)
 2) By Thermal Therapies: Hand Warmers, Thermal Gloves, Heated Pads, Biofeedback-Controlled Thermal Devices
 3) By Surgical Procedures: Sympathectomy, Nerve Decompression Surgery, Vascular Surgery
 4) By Alternative Therapies: Acupuncture, Biofeedback Therapy, Herbal Remedies, Nutritional Supplements, Stress Management Techniques
 
 Which Major Trends Are Expected to Define the Raynauds Disease Treatment Market Through 2029?
 Major companies operating in the raynauds disease treatment market are focusing on developing innovative solutions for treating raynauds disease, such as oral calcium channel blockers to improve blood flow by relaxing and widening blood vessels, thereby reducing the frequency and severity of vasospastic attacks. Oral calcium channel blocker refers to a type of medication taken by mouth that helps relax and widen blood vessels by blocking calcium entry into the muscle cells of the heart and blood vessel walls. For instance, in June 2023, Aisa Pharma Inc., a US-based clinical-stage biopharmaceutical company, launched the second part of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for treating raynaud’s phenomenon in people with systemic sclerosis (SSc). This follows promising results from the first phase, where Profervia showed a greater reduction in raynaud’s attack frequency and SSc disease severity compared to other calcium channel blockers, while also demonstrating a favorable safety profile and good tolerability. The trial, now moving forward with a 20 mg dose, aims to address the urgent need for effective treatments for Raynaud’s in SSc, a condition that currently lacks approved therapies.
 
 Which Major Organizations Influence the Direction of the Raynauds Disease Treatment Market?
 Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Concert Pharmaceuticals Inc. 
 
 Get the detailed raynauds disease treatment market report today
 https://www.thebusinessresearchcompany.com/report/raynauds-disease-treatment-global-market-report
 
 Which Region Holds the Largest Share of the Raynauds Disease Treatment Market?
 North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the raynauds disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company